Search - tctmd.com

Displaying 1 - 20 of 206

Sort: Relevancy | Date

Presentation TCT 2016

RIBS VI: A Prospective, Multicenter Registry of Bioresorbable Vascular Scaffolds in Patients With Coronary Artery Bare Metal or Drug-Eluting In-Stent Restenosis Six Month-Nine Month Clinical and Angiographic Follow-up Results

Presenter: Gary S. Mintz, Robert-Jan van Geuns, Fernando Alfonso

November 02, 2016

Presentation TCT 2016

How to Treat BRS Restenosis (With Case Examples)

Presenter: Ashok Seth, Pieter C. Smits

November 01, 2016

Presentation TCT 2016

DEBATE: DCB for In-Stent Restenosis: Does the Current Data Support Broad Adoption? Yes! The Data is Solid and DCB Should be the Treatment of Choice!

Presenter: Fernando Alfonso, Juan F. Granada, Bruno Scheller

November 01, 2016

Presentation TCT 2016

TCT 387: Sirolimus-Coated Balloons for the Prevention of Vascular Restenosis in Small Vessel Disease: Insights From the Nanoluté Registry

Presenter: Germano Di Sciascio, Bruno Scheller

November 01, 2016

Presentation TCT 2016

Sirolimus Angioplasty Balloon for In-Stent Restenosis (SABRE) Trial: 6-Month Angiographic and 1-Year Clinical Follow Up

Presenter: Fernando Alfonso, Ran Kornowski, Pieter R. Stella

November 01, 2016

Presentation TCT 2016

Nanoparticle Sirolimus Coated Balloon for the Treatment of In-Stent Restenosis: Results from the Nanolute Registry

Presenter: Fernando Alfonso, Ran Kornowski, Bernardo Cortese

November 01, 2016

Presentation TCT 2016

Case Resolution: How Did We Treat this Patient?

Presenter: Nick Curzen, Michael Mahmoudi

October 31, 2016

Presentation TCT 2016

TAVR Restenosis: Review of the Literature

Presenter: Nick Curzen

October 31, 2016

Presentation TCT 2016

Case Introduction: An 87 Year Old Woman With Recurrent Dyspnea 7 Years After TAVR

Presenter: Nick Curzen, Michael Mahmoudi

October 31, 2016

Presentation TCT 2016

TCT 52: Proportion and Morphological Features of Restenosis Lesions With Acute Coronary Syndrome in Different Timings of Target Lesion Revascularization After Sirolimus-Eluting Stent Implantation

Presenter: Michael J. Cowley, Franz-Josef Neumann, Shunsuke Kubo

October 31, 2016

Presentation TCT 2016

TCT 44: Independent Mitral Valve Restenosis Predictors After Percutaneous Mitral Balloon Valvuloplasty in a Large, Consecutive Cohort Followed for More Than Two Decades

Presenter: Stephan Baldus, Allan Schwartz, Alfredo Nunes Ferreira Neto

October 31, 2016

Presentation TCT 2016

Case Presentation: Evaluation and Management of Recurrent DES Restenosis

Presenter: Fernando Alfonso, Stephan Windecker, Adnan K. Chhatriwalla

October 30, 2016

Presentation TCT 2016

Is Brachytherapy the Best Last Hope for Recurrent DES Restenosis?

Presenter: Fernando Alfonso, Stephan Windecker, Ron Waksman

October 30, 2016

Presentation TCT 2016

Prognosis and Treatment Options for DES Restenosis and Re-restenosis

Presenter: Fernando Alfonso, Stephan Windecker

October 30, 2016

Presentation TCT 2016

Case Presentation: A Surprise in the Evaluation and Management of Stent Thrombosis

Presenter: Fernando Alfonso, Stephan Windecker, Ehrin J. Armstrong

October 30, 2016

Presentation TCT 2016

How to Evaluate and Treat the Patient With Metallic Stent Thrombosis: The Usual Suspects and Beyond

Presenter: Fernando Alfonso, Stephan Windecker, Giulio G. Stefanini

October 30, 2016

Presentation TCT 2016

Are All Stent Thromboses Prognostically Created Equal? Impact of Original Clinical Presentation, Stent Location and Thrombosis Timing

Presenter: Fernando Alfonso, Stephan Windecker, Robert-Jan van Geuns

October 30, 2016

Presentation TCT 2016

Is the OCT-derived Healing Score A Meaningful Metric to Evaluate Stent Safety?

Presenter: Fernando Alfonso, Stephan Windecker, Giulio Guagliumi

October 30, 2016

Presentation TCT 2016

OCT-assessed Rate of Early Strut Coverage: Differences Between DES and Its Implications

Presenter: Fernando Alfonso, Stephan Windecker, Stephen WL Lee

October 30, 2016

Presentation TCT 2016

Is Acute or Late Acquired Malapposition By IVUS or OCT A Risk Factor for Stent Thrombosis?

Presenter: Fernando Alfonso, Stephan Windecker, Gary S. Mintz

October 30, 2016

Advertisement

RIBS VI: A Prospective, Multicenter Registry of Bioresorbable Vascular Scaffolds in Patients With Coronary Artery Bare Metal or Drug-Eluting In-Stent Restenosis Six Month-Nine Month Clinical and Angiographic Follow-up Results

How to Treat BRS Restenosis (With Case Examples)

DEBATE: DCB for In-Stent Restenosis: Does the Current Data Support Broad Adoption? Yes! The Data is Solid and DCB Should be the Treatment of Choice!

TCT 387: Sirolimus-Coated Balloons for the Prevention of Vascular Restenosis in Small Vessel Disease: Insights From the Nanoluté Registry

Sirolimus Angioplasty Balloon for In-Stent Restenosis (SABRE) Trial: 6-Month Angiographic and 1-Year Clinical Follow Up

Nanoparticle Sirolimus Coated Balloon for the Treatment of In-Stent Restenosis: Results from the Nanolute Registry

Case Resolution: How Did We Treat this Patient?

TAVR Restenosis: Review of the Literature

Case Introduction: An 87 Year Old Woman With Recurrent Dyspnea 7 Years After TAVR

TCT 52: Proportion and Morphological Features of Restenosis Lesions With Acute Coronary Syndrome in Different Timings of Target Lesion Revascularization After Sirolimus-Eluting Stent Implantation

TCT 44: Independent Mitral Valve Restenosis Predictors After Percutaneous Mitral Balloon Valvuloplasty in a Large, Consecutive Cohort Followed for More Than Two Decades

Case Presentation: Evaluation and Management of Recurrent DES Restenosis

Is Brachytherapy the Best Last Hope for Recurrent DES Restenosis?

Prognosis and Treatment Options for DES Restenosis and Re-restenosis

Case Presentation: A Surprise in the Evaluation and Management of Stent Thrombosis

How to Evaluate and Treat the Patient With Metallic Stent Thrombosis: The Usual Suspects and Beyond

Are All Stent Thromboses Prognostically Created Equal? Impact of Original Clinical Presentation, Stent Location and Thrombosis Timing

Is the OCT-derived Healing Score A Meaningful Metric to Evaluate Stent Safety?

OCT-assessed Rate of Early Strut Coverage: Differences Between DES and Its Implications

Is Acute or Late Acquired Malapposition By IVUS or OCT A Risk Factor for Stent Thrombosis?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content